IV pentamidine is well known to cause severe multiorgan adverse effects and is usually given to hospitalized patients under close monitoring. The primary purpose of this retrospective quality assurance study is to assess the safety of administering IV pentamidine in the medical daycare unit (MDCU) for outpatients. Thirty-five outpatients infected with the HIV made 306 visits to the MDCU from January 1991 to December 1993. They received IV pentamidine in a dosage of either 300 mg once a month for prophylaxis or 4 mg/kg/d 5 days a week for treatment of Pneumocystis carinii pneumonia (PCP). BP was monitored every 15 to 30 min over 3 to 4 h and clinical side effects were noted. CBC count, BUN, creatinine, amylase, and blood glucose values were taken twice a week. The records were reviewed retrospectively and analyzed for clinical and biochemical derangement. GI side effects occurred in 59 of 306 (19%) visits; 43 (73%) of the side effects were nausea. Routine normal saline solution boluses before and after pentamidine infusion prevented the drop in BP and actually significantly elevated BP after IV pentamidine. The most common biochemical derangement was elevated BUN level in eight patients and creatinine in nine patients, but they were mild and required no intervention. Significant neutropenia occurred in three, anemia in two, hyponatremia in two, hyperamylasemia in two, and hyperglycemia in two patients. No palpitation or irregular pulse was encountered. No death was associated with the administration ofIV pentamidine. Three patients required hospital admission. Only one hospital admission was definitely related to adverse drug effects. In conclusion, the side effects of IV pentamidine are common but minor. We conclude that it is safe to administer IV pentamidine in carefully selected patients with appropriate monitoring in an ambulatory setting. This has a major health economic implication, because ambulatory IV pentamidine can result in significant cost savings and can also enhance quality oflife. Further studies regarding the feasibility of home administration of IV pentamidine is warranted as even further cost savings and improvement in the quality of life of HIV-infected patients may be achieved.
(CHEST 1996; 110:136-40) reasonably well tolerated in a retrospective study of 52 patients given IV pentamidine for both primary and secondary prophylaxis. In that study, the rate of breakthrough PCP while receiving IV pentamidine was estimated at 6 cases per 100 patient-months.
Adverse drug reactions are common with IV pentamidine.6 Rapid infusion of pentamidine can result in a precipitous fall in BP. Nephrotoxic reactions vary in severity from mild azotemia to severe acute tubular necrosis. Severe renal failure occurs in approximately 3% of pentamidine-treated patients and is associated with nearly 100% mortality.' Hypoglycemia has been observed in about 20% ofpatients and its development is unpredictable and can occur at any point during therapy.8'9 Complications resulting in major neurologic deficits and death have been reported secondary to hypoglycemia. Wharton et a18 reported that 14 of 32 (44%) patients given IV pentamidine in a prospective study had a major adverse reaction that necessitated discontinuation of the drug therapy and the remaining patients had minor adverse reactions. The most frequent major adverse reaction was neutropenia, defined as less than 1,000/mm3 (xl109/L).
As a result of the frequent and severe side effects, IV pentamidine has been almost exclusively administered in hospitalized patients, with frequent vital signs monitoring for the occurrence of side effects. We summarize our experience in the administration of IV pentamidine in the ambulatory setting over a period of 3 years. Although the use of IV pentamidine for PCP prophylaxis in the outpatient setting has been described, a careful literature search by MEDLINE did not reveal similar studies for administering daily IV pentamidine for PCP treatment in the ambulatory area. The primary purpose of this quality assurance study was to assess the safety of administering IV pentamidine for both the treatment and prophylaxis of PCP in an ambulatory setting.
MATERIALS AND METHODS

Patient Population
Thirty-five patients seropositive for HIV had 306 consecutive outpatient visits to the medical day care unit (MDCU) of the Wellesley Hospital in Toronto, Canada over a 3-year period from January 1991 to December 1993. The Wellesley Hospital is a tertiary HIV referral center fully affiliated with the University of Toronto, Toronto, Canada. The patients received IV pentamidine, 300 mg once a month for PCP prophylaxis or 4 mg/kg/d 5 times a week for treatment of PCP.
Diagnosis of PCP was made by direct immunofluorescent staining of BAL or induced sputum specimens in all 30 patients xvho received IV pentamidine for the treatment of PCP. All 30 subjects had significant allergy or intolerance to TMP/SMX, dapsone, chndamycin, and/or primaquine, and they were given IV pentamidine as there xvere no viable oral options. More than halfofthe treatment group was started on a regimen of IV pentamidine as inpatients. Those who wvere started on a regimen of IV pentamidine xvhile hospitalized xvere referred to the MDCU after their conditions improved clinically and they demonstrated no significant side effects to daily IV pentamidine over a 5-to 7-day period to complete a total of 3 weeks of treatment. For the remainder ofthe treatment group, the episodes of PCP were mild enough to be treated on an outpatient basis for the entire 3 weeks. The subjects who received IV pentamidine for PCP prophylaxis were all initiated as outpatients.
Staffing and Capabilities of the MDCU
The MDCU at the Wellesley Hospital was located on a medical floor where there was also a ten-bed HIV inpatient unit. There were six beds in the MDCU for medical patients requiring investigative procedures or day treatment. The health-care team consisted of a clinical fellow and two registered nurses experienced in the care of HIV-infected patients, including the insertion and care of midline catheters. Every patient coming for IV pentamidine for the first No. of visits 9 14 32 of the patient, survey for possible side effects of IV pentamidine, and do the necessary blood tests according to the protocols (Tables  1 and 2 ).
IV Pentamoidine Protocol Pentamidine was infused IV over 1 to 2 h. A peripheral midline IV catheter was inserted for IV access. Patients were monitored for svmptoms suggestive of side effects. These included nausea, vomiting, GI upset, skin rash, and symptoms of hypoglycemia or hypocalcemia. BP was monitored every 15 to 30 min during IV pentamidine infusion. A change in the mean arterial pressure (MAP) of greater than or equal to 10 mm Hg was considered significant. If the drop in BP was significant or patients were symptomatic, normal saline solution boluses were given. Beginning in January 1993, we implemented a protocol in which normal saline solution boluses wvere given routinely both before and after pentamidine infusion to try to reduce the incidence ofhypotension. The protocol for giving IV pentamidine for the prophylaxis of PCP (Table 1) varied slightly from that for the treatment of PCP (Table 2 ).
Adverse Events Surveillance
Routine blood tests, including CBC counts, serum electrolytes, BUN and creatinine, amylase, and blood glucose xvere done twice wveekly in the treatment group (Table 2) and only once a month in the prophylaxis group (Table 1) . Serum calcium and magnesium levels vere not checked as a routine unless there vere signs or symptoms suggestive of any derangement. ECG was also not part of the routine protocol unless there were cardiac symptoms. Patients xvere asked about adverse or untoward events that developed after discharge from the MDCU on subsequent IV pentamidine visits.
Outcomnes
The primary end points of the study were clinical and biochemical side effects associated with IV pentamidine. Significant biochemical abnormalities were defined as folloxvs: hemoglobin less than 8 g/dL (S0 g/L); neutrophil count less than 1,000/mm3 (lx 109/L); platelet count less than 50,000/mm3 (50x1012/L); serum sodium less than 135 mEq/L (135 mmol/L); serum potassium less than 3.5 or greater than 5.0 mEq/L (mmol/L); BUN greater than 18 mg/dL (6.7 mmol/L); serum creatinine greater than 1.4 g/dL (20 pmol/L); serum amylase greater than 300 U/L; and blood glucose less than 45 nmg/dL (2.5 mmol/L) or greater than 108 mg/dL (6.0 mmol/L). The secondary end points were the need for hospitalization and death.
Statistics
The results were reviexved retrospectively and the data were tabulated and analyzed xvhere appropriate with the x2 test for statistical significance. A p value of <0.05 was considered statistically significant. 
RESULTS
Thirty-five HIV-positive patients had 306 consecutive outpatient visits to the MDCU for IV pentamidine from January 1991 to December 1993. They were all male with age ranging from 25 to 46 years, with a mean of 34 years. Over the 3-year study period, there was an increase in administration of IV pentamidine in the outpatient setting (Table 3 ). For the 3-year study period, the average length of time receiving IV pentamidine for PCP prophylaxis was about 5 months. Some of the patients died, some were desensitized to TMP/ SMX or dapsone, and others switched to aerosol pentamidine.
The most common side effect was nausea, documented in 43 of 306 (14.1%) visits (Table 4 ). The other less frequent adverse events were vomiting, occurring in 2.3% of the visits, involving 5 patients, abdominal discomfort affecting 15 patients (2.3% visits, 5 patients), and diarrhea (0.7%, 2 patients). No palpitation or irregular pulse was encountered.
In 1991 and 1992 when normal saline solution was given only if the BP fell, there was a significant drop in MAP defined as greater than 10 mm Hg in 18 visits (10.8%) affecting 10 patients. In 1993, when normal saline solution boluses were given routinely before and after IV pentamidine, there was a trend toward fewer instances ofsignificant fall in the MAP observed in nine visits affecting seven patients, but the results did not reach statistical significance (p>0.25). However, a significant rise in MAP over 10 mm Hg occurred in 13 visits (9.3%) in 1993 when prophylactic IV boluses of normal saline solution were given compared to 6 visits (3.6%) in 1991 and 1992 (p<0.05) ( Table 5 ). Most of the observed changes in MAP were mild as severe hypotension defined as systolic BP less than 80 mm Hg occurred in only four visits. On one occasion, the BP remained low despite normal saline solution boluses, and hospitalization was needed. The patient was subsequently found to have cellulitis from an infected midline IV catheter. The most common laboratory abnormality after IV pentamidine was an elevated BUN and creatinine value, occurring in 22.9% and 25.7% of patients, respectively (Table 6 ). However, the impairment in renal function was mild and none required withdrawal of the drug therapy or dialysis. Rise in BUN and creatinine value was observed only in the group ofpatients receiving IV pentamidine for PCP treatment, and the BUN and creatinine values returued to baseline levels after the completion of the treatment course with IV pentamidine. Neutropenia, anemia, hyponatremia, hyperglycemia, and hyperamylasemia occurred infrequently (Table 6 ). There was no systemic sepsis as a result of neutropenia. There was no episode of clinically significant hypoglycemia, hyperkalemia, or thrombocytopenia during the infusion. When patients were asked regularly on follow-up visits, no untoward events due to hypoglycemia or metabolic disturbance occurred after the patients were discharged from the MDCU.
Three patients required admission into the hospital from the MDCU after IV pentamidine over the 3-year study period, one in each year. Only one of them was related to adverse drug reaction to pentamidine-hypotension together with mild renal insufficiency (creatinine, 1.9 mmg/dL) and hypocalcemia. The other two patients had weakness and numbness on one side ofthe body and cellulitis from an infected midline catheter mentioned above. There was no death related to IV pentamidine during the study period.
Cost-effectiveness of the Outpatient IV Pentamidine
Program
Estimates from the cost centers at the Wellesley Hospital indicate that the cost of IV pentamidine, supplies, and equipment was about $80 Canadian ($60 US) per visit. The nursing cost was estimated at $120 Canadian ($90 US) per visit. Therefore, the cost of one visit to the MDCU for IV pentamidine infusion was approximately $200 Canadian ($150 US). The average cost of one hospitalization in Ontario, Canada, at the time of the study was well over $1,000 Canadian ($750 US). Thus, outpatient IV pentamidine is less than one fifth of the cost of inpatient treatment for IV pentamidine. These simple cost analyses for outpatient IV pentamidine treatment clearly favor its use, especially since the frequency and cost of failure/complication were surprisingly low in these carefully selected patients.
DISCUSSION
To our knowledge, this is the first reported experience on the administration of IV pentamidine for the prophylaxis and treatment of PCP in the ambulatory setting. From previous studies, side effects were frequently reported with the use of IV pentamidine. When IV pentamidine was used on outpatients in apparently stable conditions or prophylaxis as a 2-to 4-h infusion in a dose of 4 mg/kg body weight biweekly, drug toxic reactions were reported in 17 of 42 (40%) patients and led to discontinuation of IV pentamidine therapy in 3 patients. 4 Ena et al5 reported side effects associated with IV pentamidine administration in 36 patients (69%) but did not specify the number of episodes of side effects for each patient. Hypotension and hypoglycemia were usually transient and mild, and did not necessitate discontinuation of the infusion.5 When given for PCP treatment, Wharton et a18 reported that all patients receiving IV pentamidine experienced minor adverse reactions and 44% of patients had a major adverse reaction requiring discontinuation of the drug treatment. In a recent randomized controlled trial of IV pentamidine against oral atovaquone, Dohn et al10 found that treatment-limiting adverse events necessitating discontinuation of original therapy were significantly more frequent in the pentamidine-treated group (36%). This contrasts markedlywith our findings in this study. We found that although the side effects of daily IV pentamidine for the treatment of PCP were frequent, they were generally minor. Only one patient had adverse drug reaction related to IV pentamidine severe enough to warrant hospitalization. There was no death directly related to the use of IV pentamidine.
The major difference between the present study and the previous reports lies in patient selection. In our study, the patients were either in a clinically stable condition and came to the MDCU only for IV pentamidine for PCP prophylaxis or mild episodes of PCP. The sicker or less stable patients with moderate to severe PCP were started on a regimen ofIV pentamidine as inpatients and clearly demonstrated tolerance with clinical improvement over 5 to 7 days prior to dis-charging to the MDCU for the balance of daily IV pentamidine treatments. Our results suggest that wvith careful patient selection, IV pentamidine can be administered safely in an ambulatory setting for both the prophylaxis and treatment of PCP. 1993, we routinely gave 500 mL of normal saline solution over 1 h both before and after pentamidine infusion. This resulted in a trend toward not only prevention of significant drop in the MAP, but actually induced a slight increase in the MAP. The normal saline solution boluses were well tolerated by the patients and did not precipitate any episode of clinical congestive heart failure. Despite prolonging the patient's duration of stay to 3 to 4 h, the routine normal saline solution boluses wvere still feasible in the MDCU.
The outpatient IV pentamidine program has a tremendous cost reduction implication. In an era when the cost of inpatient care is constantly escalating, wvays to shorten the length of stay are most welcome. The health-care savings from the IV pentamidine program can be channelled into other areas of the health-care system to maintain the same high quality of care. XVe have shown that wvith careful patient selection and appropriate monitoring, administration of IV pentamidine wvas safe and can reduce or avoid the cost of hospitalization. Not only will there be enormous cost savings but the patients will also benefit from early discharge, and this can lead to improved quality of life.
Further study in the feasibility of home IV pentamidine administration by the home-care team is warranted. If proved to be safe, it will lead to further health-care savings an(d enhanced quality of life.
